Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BalanGluco is a dietary supplement developed by Hi-Q Marine Biotech International for the management of diabetes and blood sugar regulation. Its primary functional ingredient is FucoBalan, a proprietary marine-derived complex combining low molecular weight oligo fucoidan (extracted from *Laminaria japonica*) and high-stability fucoxanthin. The formulation also includes digestion-resistant maltodextrin (Fibersol-2), bitter melon extract containing peptides, and chromium polynicotinate (ChromeMate). BalanGluco is designed to modulate blood glucose levels, enhance metabolism, and support liver and heart function. It has been evaluated in human clinical trials and is manufactured under GMP and ISO standards.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BalanGluco.